Travoprost: Intracameral Implantation: Intracameral Vascular Implantation: Intracameral Vascular Imp

An international medical study has yielded new findings with relevant findings that are of important reference value for the Cope for Disease Prevention. The main objective of this study is to report the main and secondary real-world outcomes of TR, travoprost intracameral implants. The secondary objective of this study is to compare the therapeutic effects of different groups by type of surgery, severity and characteristics such as race/ethnicity.

This is the case of retrospective non-random single-centered sequence of cases of iDose TR implantation initiation, or without MIGS. The inclusion criteria were mainly open angular blue eyes, with light to severe stages, and a follow-up period of at least 3 months. Joint surgery was also performed on the eyes with visual significance.

The corresponding continuous artificial crystalline surgery was carried out. The median and proportional analysis of blood pressure and drug burden (baseline vs. 3 months later) was carried out.

A total of 85 eyes participated in the study. Combined use of iDose Unlimited (n=22) and iDose Unlimited (n=16) on the basis of iDose Unlimited (n=22) and iDose Unlimited (n=16) respectively, median and proportional analysis of drug burden (baseline vs. 3 months later) was carried out.

A total of 85 eyes participated in the study. Combined use of iDose Unlimited (n=22) and iDose Unlimited (n=16) on the basis of iDose Unlimited (n=22) and iDose Unlimited (n=16) respectively, median and proportional analysis of drug burden (baseline vs. 3 months later) was conducted.

A total of 85 eyes participated in the study. The combined use of iDose Unlimited (n=22) and iDose Unlimited (n=16) on the basis of iDose Unlimited (n=22) and iDose Unlimited (n=16) respectively, has led to a median and proportional analysis of the drug burden (baseline vs. 3 months later).